Trials / Completed
CompletedNCT05209906
An Observation Study to Assess the Efficacy and Safety of Proportional Doses of Painkyl® in Patients With Breakthrough Cancer Pain
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 37 (actual)
- Sponsor
- Mackay Memorial Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
An open-label, single arm, observation study, to assess the efficacy and safety of proportional doses of Painkyl® in patients with breakthrough cancer pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fentanyl Buccal Soluble Film | Eligible patients will receive Painkyl® for dose of 200, 400, 600, 800, 1000 or 1200 mcg for the treatment of breakthrough pain according to around-the-clock morphine daily dose. |
Timeline
- Start date
- 2019-11-06
- Primary completion
- 2022-08-15
- Completion
- 2022-08-15
- First posted
- 2022-01-27
- Last updated
- 2022-08-23
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT05209906. Inclusion in this directory is not an endorsement.